This shows a woman's face and psychedelic swirls.
The scientists also provide a new look at molecular mechanisms impacted by psychedelics. Credit: Neuroscience News

Psychedelics Unlock Learning Windows in the Brain

Summary: Researchers discovered a unique property of psychedelic drugs: their ability to reopen “critical periods” in the brain, times when the brain is highly susceptible to environmental learning signals. These periods, usually associated with skills development like language learning, are reopened by psychedelics for different lengths of time.

This breakthrough in understanding psychedelic drug function may have therapeutic implications for conditions like stroke and deafness. Further, it uncovers novel molecular mechanisms influenced by psychedelics.

Key Facts:

  1. Psychedelic drugs, including ibogaine, ketamine, LSD, MDMA, and psilocybin, can reopen the “critical periods” of brain development in mice, making them more receptive to learning from their environment.
  2. The length of these reopened critical periods varies depending on the psychedelic drug used, ranging from 48 hours with ketamine to four weeks with ibogaine.
  3. The study also identified molecular mechanisms influenced by psychedelics, including 65 protein-producing genes that show expression differences during and after the critical period.

Source: Johns Hopkins University

Neuroscientists have long searched for ways to reopen “critical periods” in the brain, when mammals are more sensitive to signals from their surroundings that can influence periods of brain development.

Now, researchers at Johns Hopkins Medicine say a new study in mice shows that psychedelic drugs are linked by their common ability to reopen such critical periods, but differ in the length of time the critical period is open—from two days to four weeks with a single dose.

The findings, published June 14 in the journal Nature, provide a new explanation for how psychedelic drugs work, say the scientists, and suggest potential to treat a wider range of conditions, such as stroke and deafness, beyond those in current studies of the drugs, such as depression, addiction and post-traumatic stress disorder.

The scientists also provide a new look at molecular mechanisms impacted by psychedelics.

Critical periods have been demonstrated to perform such functions as help birds learn to sing and help humans learn a new language, relearn motor skills after a stroke and establish dominance of one eye over the other eye.

“There is a window of time when the mammalian brain is far more susceptible and open to learning from the environment,” says Gül Dölen, M.D., Ph.D., associate professor of neuroscience at the Johns Hopkins University School of Medicine.

“This window will close at some point, and then, the brain becomes much less open to new learning.”

Building on her laboratory’s experience studying social behavior, Dölen’s team has been researching how psychedelic drugs work by reopening these critical periods. In 2019, her team found that MDMA, a psychedelic drug that arouses feelings of love and sociability, opens a critical period in mice.

At the time, Dölen thought MDMA’s prosocial properties smooth the way for opening the critical period, but her team was surprised, she says, to find in the current study that other psychedelic drugs without prosocial properties could also reopen critical periods.

For the current study, Dölen’s team looked at the reopening potential of five psychedelic drugs—ibogaine, ketamine, LSD, MDMA and psylocibin—shown in numerous studies as able to change normal perceptions of existence and enable a sense of discovery about one’s self or the world.

The research team conducted a well-established behavioral test to understand how easily adult male mice learn from their social environment. They trained mice to develop an association between an environment linked with social interaction versus another environment connected with being by themselves.

By comparing time spent in each environment after giving the psychedelic drug to the mice, the researchers were able to see if the critical period opened in the adult mice, enabling them to learn the value of a social environment—a behavior normally learned as juveniles.

For mice given ketamine, the critical period of social reward learning stayed open in the mice for 48 hours. With psilocybin, the open state lasted two weeks. For mice given MDMA, LSD and ibogaine, the critical period remained open for two, three and four weeks, respectively.

The researchers say the length of time that the critical period stayed open in mice seems to roughly parallel the average length of time that people self-report the acute effects of each psychedelic drug.

“This relationship gives us another clue that the duration of psychedelic drugs’ acute effects may be the reason why each drug may have longer or shorter effects on opening the critical period,” says Dölen.

“The open state of the critical period may be an opportunity for a post-treatment integration period to maintain the learning state,” she adds.

“Too often, after having a procedure or treatment, people go back to their chaotic, busy lives that can be overwhelming. Clinicians may want to consider the time period after a psychedelic drug dose as a time to heal and learn, much like we do for open heart surgery.”

Next, the scientists looked at psychedelic drugs’ impact on molecular mechanisms. First, in mouse brain cells, they examined a binding point, known as a receptor, for the neurotransmitter serotonin.

The researchers found that while LSD and psilocybin use the serotonin receptor to open the critical period, MDMA, ibogaine and ketamine do not.

To explore other molecular mechanisms, the research team turned to ribonucleic acid (RNA), a cousin to DNA that represents which genes are being expressed (producing proteins) in the mice’s cells.

The researchers found expression differences among 65 protein-producing genes during and after the critical period was opened.

About 20% of these genes regulate proteins involved in maintaining or repairing the extracellular matrix—a kind of scaffolding that encases brain cells located in the nucleus accumbens, an area associated with social learning behaviors that are responsive to rewards.

Others who helped conduct the research were Romain Nardou, Edward Sawyer, Young Jun Song, Makenzie Wilkinson, Yasmin Padovan-Hernandez, Júnia Lara de Deus, Noelle Wright, Carine Lama, Sehr Faltin, Loyal Goff and Genevieve Stein-O’Brien from Johns Hopkins.

About this psychopharmacology and neuroscience research news

Author: Gül Dölen
Source: Johns Hopkins Medicine
Contact: Gül Dölen – Johns Hopkins Medicine
Image: The image is credited to Neuroscience News

Original Research: Closed access.
Psychedelics Reopen the Social Reward Learning Critical Period” by Gül Dölen et al. Nature


Psychedelics Reopen the Social Reward Learning Critical Period

Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness.

These drugs have been used for millennia in both spiritual and medicinal contexts, and a number of recent clinical successes have spurred a renewed interest in developing psychedelic therapies.

Nevertheless, a unifying mechanism that can account for these shared phenomenological and therapeutic properties remains unknown.

Here we demonstrate in mice that the ability to reopen the social reward learning critical period is a shared property across psychedelic drugs. Notably, the time course of critical period reopening is proportional to the duration of acute subjective effects reported in humans.

Furthermore, the ability to reinstate social reward learning in adulthood is paralleled by metaplastic restoration of oxytocin-mediated long-term depression in the nucleus accumbens.

Finally, identification of differentially expressed genes in the ‘open state’ versus the ‘closed state’ provides evidence that reorganization of the extracellular matrix is a common downstream mechanism underlying psychedelic drug-mediated critical period reopening.

Together these results have important implications for the implementation of psychedelics in clinical practice, as well as the design of novel compounds for the treatment of neuropsychiatric disease.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.